- Number of Downgrades
- 18 (in the last 90 days)
- Consensus Rating
- Hold
- Rating Score
- 2.1
- Ratings Breakdown
- 3 Buy Ratings, 9 Hold Ratings, 2 Sell Ratings.
- Consensus Price Target
- $7.00 (490.7% Upside)
About Editas Medicine
Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Read More
Recent Analyst Ratings
More Investing Slideshows: